Liposomal BCL Inhibitors for Hyperproliferative Disorders
Summary
USPTO published patent application US20260108534A1 on April 23, 2026, filed September 30, 2025 under Application No. 19345495. The application covers liposomes containing B-cell lymphoma (Bcl) protein inhibitors, pharmaceutical compositions thereof, and methods of using such formulations for treating hyperproliferative disorders. Inventors: Paul Tardi, Leon Wan, Shyam Madhusudan Garg, Jun Gao, and Philippe Legros.
“Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108534A1 for liposomal formulations of BCL inhibitors for treating hyperproliferative disorders. The application names five inventors and covers compositions and methods of treatment using the disclosed formulations. Patent applications do not create immediate compliance obligations; they establish a priority date and initiate the examination process. Pharmaceutical manufacturers and biotech companies developing Bcl protein inhibitors or liposomal drug delivery systems may want to monitor this application's prosecution for potential freedom-to-operate considerations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LIPOSOMAL FORMULATIONS OF BCL INHIBITORS
Application US20260108534A1 Kind: A1 Apr 23, 2026
Inventors
Paul TARDI, Leon WAN, Shyam Madhusudan GARG, Jun GAO, Philippe LEGROS
Abstract
Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.
CPC Classifications
A61K 31/635 A61K 9/127 A61K 9/1271 A61K 9/1272 A61K 9/1277 A61K 45/06 A61K 47/186 A61K 47/20 A61K 47/26 A61K 47/28 A61P 7/04
Filing Date
2025-09-30
Application No.
19345495
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.